Ali Tabassian
Ophthalmology · Richmond, VANPI 1679535538
Payments from drug & device makers
What this record shows
This record is dominated by gifts: $4,068 of the $4,452 with a category attached, or 91.4%. Carl Zeiss Meditec, Inc. accounts for 91.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $2,872 and has fallen 99.1% since, to $25 in 2025.
Across 15 payments — averaging $296.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$4K
- Genentech USA, Inc.$161
- Genentech, Inc.$72
- AbbVie$65
- Alimera Sciences, Inc.$35
- Regeneron Healthcare Solutions, Inc.$30
- plus $20 from 1 others
Across 117 payments — averaging $18,305 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$2.1M
- Bayer$774
What the payments were for
- Food & beverage$3849%
- Gifts$4,06891%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 4 | $4,068 |
| Genentech USA, Inc. | 3 | $161 |
| Genentech, Inc. | 1 | $72 |
| AbbVie(2 entities) | 3 | $65 |
| Alimera Sciences, Inc. | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Novartis | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CIRRUS HD-OCT$2,372
- CLARUS 500 Fundus Camera$1,092
- CLARUS$603
How this compares
$4,452 in reported general payments places this provider in the 85th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 142 | $5,036 |
| Latanoprost | 110 | $873 |
| Timolol Maleate | 88 | $854 |
| Brimonidine Tartrate | 63 | $792 |
| Ofloxacin | 55 | $659 |
| Dorzolamide Hcl | 15 | $364 |
| ErythromycinErythromycin Base | 23 | $282 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 14 | $174 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 11 | $135 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Richmond
- Ethnie JonesRichmond$2M
- Thomas JenkinsRichmond$26K
- Jessica RandolphRichmond$18K
- Nikisha RichardsRichmond$16K
- Tam DangRichmond$9K
- Byron LaddRichmond$7K
- Bryan SchwentRichmond$7K
- Rishi ParikhRichmond$6K
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.